drug supply became unavailable

This is a Phase II, open label, fixed dose, repeat injection, single institution study. Eligible subjects will receive up to six doses of Ad-ISF35 injected directly into a selected lymph node under ultrasound guidance. The primary goal is to determine and monitor clinical and biological responses in patients treated with repeat intranodal injections of Ad-ISF35.

This is a phase II clinical trial in which study subjects will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.

Because this is the first time that repeat administration of Ad-ISF35 will be performed via intranodal injection, and in order to allow sufficient time to evaluate the safety and toxicity of this procedure, we will treat subjects 1 thru 3 at one month intervals and with inpatient admission for 24 hours observation. After subject three receives their second ISF35 injection we will proceed with enrollment of cohorts of four patients per month at one week intervals until study enrollment has been completed. These subjects will be treated as outpatients and will be observed for 3 hours prior to discharge.

ISF35 has already been used in Phase I clinical trials. The trials demonstrated that ISF35 treatment is well-tolerated and patients did not experience any significant or unexpected adverse events. Patients reported flu-like symptoms from ISF35, which disappeared within one to three days.

ISF35 is an abbreviation for Immune Stimulatory Factor 35, an offspring of technology discovered by Dr. Thomas J. Kipps, MD, PhD, Professor, Department of Medicine and Deputy Director for Research,UCSD Moores Cancer Center.

Inclusion Criteria:

1. Diagnosis of B-cell CLL/SLL including:

   • Lymphocytosis of monoclonal B-cells co-expressing ≥ one B-cell marker (CD19, CD20, or CD23) AND
   • CD5 in peripheral blood or lymph node AND
   • Bone marrow with ≥ 30% mononuclear cells having the CLL/SLL phenotype.

2. Presence of at least ONE single accessible AND palpable lymph node in the cervical, supraclavicular, axillary, or inguinal regions. The size of the lymph nodes must be larger than 2x2 cm in the horizontal and perpendicular axes.

3. Intermediate or High risk, poor prognosis CLL/SLL

4. Indication for treatment as defined by the NCI Working Group Guidelines:

   • Massive (> 6 cm below the left costal margin) or progressive splenomegaly OR
   • Massive lymph nodes or nodal clusters (> 10 cm in longest diameter) OR *Progressive lymphadenopathy OR
   • Grade 2 or 3 fatigue OR
   • Fever ≥ 100.5 degrees F OR
   • Night sweats for greater than 2 weeks without documented infection OR
   • Presence of weight loss ≥ 10% over the preceding 6 months OR
   • Progressive lymphocytosis with an increase of ≥ 50% over a 2-month period OR
   • An anticipated doubling time of less than 6 months.
   • Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia.
   • Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroid therapy.

5. Males and females 18 years of age and older

6. Laboratory parameters as specified below:

   • Hematologic: Hemoglobin ≥ 10 g/dL (may be post-transfusion); platelet count ≥ 50x10^3/mm^3
   • Hepatic: Total Bilirubin < 2 x ULN, and ALT and AST < 2 x ULN
   • Renal: Creatinine ≤ 2 x ULN

7. ECOG Performance Status ≤ 2

8. Anticipated survival of at least 3 months

9. For men and women of child-producing potential, use of effective barrier contraceptive methods during the study and for one month following treatment.

10. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.

11. Negative test results for current/active infection with HIV-1, HIV-2, HTLV-1, HTLV-2, CMV, hepatitis A, B, C within 30 days of registration. (Antibody, antigen and nucleic acid tests acceptable, depending on institutional standards.).

12. Subjects must give written informed consent to participate in this trial.

13. Subjects must have received treatment for CLL with chemotherapy agents or antibodies OR if subjects are previously untreated they must state in the consent form that they are refusing to be treated with chemotherapy or antibodies.

Exclusion Criteria:

1. Pregnant or nursing women.
2. Treatment with chemotherapy or monoclonal antibody within 28 days prior to entering the study.
3. Treatment with chemotherapy or monoclonal antibody during the time of participation in this trial.
4. Grade 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification.
5. Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, COPD).
6. Participation in any investigational drug study within 28 days prior to ISF35 administration. (Patient must have recovered from all acute effects of previously administered investigational agents)
7. History of malignancy other than CLL within five years of registration, except patients with adequately treated basal, squamous cell carcinoma or localized cervical cancer.
8. Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis.
9. Any illness or condition that in the opinion of the Investigator may affect safety of treatment or evaluation of any the study's endpoints.